Alastair Kent, speaking at World Orphan Drug Congress 2011

Alastair Kent,
Director
Genetic Alliance UK

Alastair Kent is the Director of Genetic Alliance UK – the national charity of over 140 patient organisations, supporting all those affected by genetic conditions. Genetic Alliance UK’s mission is to promote the development of the scientific understanding of genetics and the part that genetic factors play in health and disease, and to see the speedy transfer of this new knowledge into improved services and support for the treatment of currently incurable conditions.

Alastair is also the Chair of Rare Disease UK, the national multi-stakeholder alliance campaigning for, and informing the development of, a strategy for rare diseases in the UK.

Alastair has worked in the field of genetic and rare disease healthcare for over 20 years. Alastair represents the interests of patients on numerous platforms; he is the president of the European Genetic Alliances Network (EGAN), Director of the European Platform for Patient Organisations, Science and Industry (EPPOSI), a member of the EU Committee of Experts on Rare Diseases and the European Medicine Agency’s Committee for Advanced Therapies amongst others.

Appearing:

World Orphan Drug Congress Day 2 Wednesday 30th November 2011

10am

Panel discussion: Engaging in an open dialogue throughout the clinical trial stage

Unprecedented clinical trials require established validity of primary endpoints
When and how should all stakeholders communicate during orphan drug development?
How can market approval be optimised during the clinical stages?
Where has open dialogue bred success and where have talks broken down?

Annie-Claude Benichou,

CMO,
Alaxia

Thomas Meier,

CSO,
Santhera Pharmaceuticals

Alastair Kent,

Director,
Genetic Alliance UK

An Van Es-Johansson,

Head of Clinical Development,
Swedish Orphan Biovitrum

Sponsor World Orphan Drug Congress 2011 ›

Associate Sponsor